Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial
The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.